ScinoPharm Taiwan, Ltd.
TWSE:1789.TW
23 (TWD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,186.083 | 3,264.045 | 2,762.335 | 3,082.928 | 2,892.783 | 3,524.263 | 3,516.481 | 4,030.921 | 3,955.207 | 4,097.844 | 5,088.245 | 4,572.509 | 3,953.578 | 3,891.113 | 3,813.072 |
| Cost of Revenue
| 1,970.094 | 2,013.273 | 1,481.848 | 1,765.469 | 1,716.378 | 1,981.749 | 1,966.324 | 2,224.96 | 2,278.553 | 2,497.278 | 2,545.712 | 2,259.081 | 1,969.16 | 1,857.144 | 1,913.639 |
| Gross Profit
| 1,215.989 | 1,250.772 | 1,280.487 | 1,317.459 | 1,176.405 | 1,542.514 | 1,550.157 | 1,805.961 | 1,676.654 | 1,600.566 | 2,542.533 | 2,313.428 | 1,984.418 | 2,033.969 | 1,899.433 |
| Gross Profit Ratio
| 0.382 | 0.383 | 0.464 | 0.427 | 0.407 | 0.438 | 0.441 | 0.448 | 0.424 | 0.391 | 0.5 | 0.506 | 0.502 | 0.523 | 0.498 |
| Reseach & Development Expenses
| 357.74 | 271.264 | 305.953 | 245.633 | 238.373 | 313.208 | 314.276 | 279.575 | 324.214 | 415.888 | 417.875 | 303.023 | 291.452 | 302.185 | 327.872 |
| General & Administrative Expenses
| 364.174 | 406.532 | 532.225 | 525.418 | 513.796 | 524.047 | 531.163 | 488.139 | 445.701 | 447.541 | 538.715 | 565.811 | 390.724 | 340.122 | 312.088 |
| Selling & Marketing Expenses
| 179.651 | 167.343 | 153.566 | 170.904 | 157.168 | 146.931 | 145.756 | 169.971 | 157.036 | 177.695 | 188.443 | 185.346 | 168.811 | 169.094 | 93.392 |
| SG&A
| 543.825 | 573.875 | 685.791 | 696.322 | 670.964 | 670.978 | 676.919 | 658.11 | 602.737 | 625.236 | 727.158 | 751.157 | 559.535 | 509.216 | 405.48 |
| Other Expenses
| 0 | 18.256 | 0.835 | -29.46 | 53.889 | 12.298 | -7.029 | -21.56 | 61.445 | 62.404 | 35.72 | 110.994 | 41.463 | 60.876 | -7.829 |
| Operating Expenses
| 901.565 | 845.139 | 991.744 | 941.955 | 909.337 | 984.186 | 991.195 | 937.685 | 926.951 | 1,041.124 | 1,145.033 | 1,054.18 | 850.987 | 811.401 | 733.352 |
| Operating Income
| 357.92 | 446.009 | 308.958 | 373.452 | 320.957 | 558.328 | 558.962 | 868.276 | 749.703 | 559.442 | 1,397.5 | 1,259.248 | 1,133.431 | 1,222.568 | 1,166.081 |
| Operating Income Ratio
| 0.112 | 0.137 | 0.112 | 0.121 | 0.111 | 0.158 | 0.159 | 0.215 | 0.19 | 0.137 | 0.275 | 0.275 | 0.287 | 0.314 | 0.306 |
| Total Other Income Expenses Net
| -9.08 | -8.049 | -6.672 | -16.999 | -2.014 | -67.787 | -83.66 | -57.676 | 53.181 | 42.767 | 11.013 | 116.853 | 57.039 | -26.772 | -62.531 |
| Income Before Tax
| 348.84 | 437.96 | 302.286 | 358.505 | 265.054 | 490.541 | 475.302 | 810.6 | 802.884 | 602.209 | 1,408.513 | 1,371.667 | 1,135.315 | 1,195.796 | 1,103.55 |
| Income Before Tax Ratio
| 0.109 | 0.134 | 0.109 | 0.116 | 0.092 | 0.139 | 0.135 | 0.201 | 0.203 | 0.147 | 0.277 | 0.3 | 0.287 | 0.307 | 0.289 |
| Income Tax Expense
| 61.784 | 84.744 | 58.815 | 76.438 | 48.398 | 47.563 | 52.935 | 151.907 | 167.919 | 118.066 | 135.109 | 201.245 | 173.998 | 155.841 | 64.256 |
| Net Income
| 287.056 | 353.216 | 243.471 | 282.067 | 216.656 | 442.978 | 422.367 | 658.693 | 634.965 | 484.143 | 1,273.404 | 1,170.469 | 959.355 | 1,040.003 | 1,041.033 |
| Net Income Ratio
| 0.09 | 0.108 | 0.088 | 0.091 | 0.075 | 0.126 | 0.12 | 0.163 | 0.161 | 0.118 | 0.25 | 0.256 | 0.243 | 0.267 | 0.273 |
| EPS
| 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | 0.56 | 0.53 | 0.83 | 0.81 | 0.61 | 1.61 | 1.48 | 1.24 | 1.44 | 1.51 |
| EPS Diluted
| 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | 0.56 | 0.53 | 0.83 | 0.8 | 0.61 | 1.61 | 1.48 | 1.24 | 1.44 | 1.51 |
| EBITDA
| 819.087 | 885.474 | 690.49 | 766.649 | 729.672 | 964.233 | 984.472 | 1,291.557 | 1,232.222 | 1,092.947 | 1,845.018 | 1,739.888 | 1,483.05 | 1,583.88 | 1,510.483 |
| EBITDA Ratio
| 0.257 | 0.271 | 0.25 | 0.249 | 0.252 | 0.277 | 0.28 | 0.32 | 0.327 | 0.263 | 0.366 | 0.375 | 0.379 | 0.398 | 0.398 |